IBDEI0US ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14167,1,4,0)
 ;;=4^H54.2
 ;;^UTILITY(U,$J,358.3,14167,2)
 ;;=^5006361
 ;;^UTILITY(U,$J,358.3,14168,0)
 ;;=H54.3^^82^773^8
 ;;^UTILITY(U,$J,358.3,14168,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14168,1,3,0)
 ;;=3^Unqualified Visual Loss,Both Eyes
 ;;^UTILITY(U,$J,358.3,14168,1,4,0)
 ;;=4^H54.3
 ;;^UTILITY(U,$J,358.3,14168,2)
 ;;=^268886
 ;;^UTILITY(U,$J,358.3,14169,0)
 ;;=H54.41^^82^773^5
 ;;^UTILITY(U,$J,358.3,14169,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14169,1,3,0)
 ;;=3^Blindness-Right Eye/Normal Vision-Left Eye
 ;;^UTILITY(U,$J,358.3,14169,1,4,0)
 ;;=4^H54.41
 ;;^UTILITY(U,$J,358.3,14169,2)
 ;;=^5006363
 ;;^UTILITY(U,$J,358.3,14170,0)
 ;;=H54.42^^82^773^3
 ;;^UTILITY(U,$J,358.3,14170,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14170,1,3,0)
 ;;=3^Blindness-Left Eye/Normal Vision-Right Eye
 ;;^UTILITY(U,$J,358.3,14170,1,4,0)
 ;;=4^H54.42
 ;;^UTILITY(U,$J,358.3,14170,2)
 ;;=^5133518
 ;;^UTILITY(U,$J,358.3,14171,0)
 ;;=H54.7^^82^773^9
 ;;^UTILITY(U,$J,358.3,14171,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14171,1,3,0)
 ;;=3^Visual Loss,Unspec
 ;;^UTILITY(U,$J,358.3,14171,1,4,0)
 ;;=4^H54.7
 ;;^UTILITY(U,$J,358.3,14171,2)
 ;;=^5006368
 ;;^UTILITY(U,$J,358.3,14172,0)
 ;;=H54.8^^82^773^6
 ;;^UTILITY(U,$J,358.3,14172,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14172,1,3,0)
 ;;=3^Legal Blindness,as Defined in USA
 ;;^UTILITY(U,$J,358.3,14172,1,4,0)
 ;;=4^H54.8
 ;;^UTILITY(U,$J,358.3,14172,2)
 ;;=^5006369
 ;;^UTILITY(U,$J,358.3,14173,0)
 ;;=E11.9^^82^774^26
 ;;^UTILITY(U,$J,358.3,14173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14173,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,14173,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,14173,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,14174,0)
 ;;=E11.39^^82^774^15
 ;;^UTILITY(U,$J,358.3,14174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14174,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complications
 ;;^UTILITY(U,$J,358.3,14174,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,14174,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,14175,0)
 ;;=E11.36^^82^774^14
 ;;^UTILITY(U,$J,358.3,14175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14175,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Cataract
 ;;^UTILITY(U,$J,358.3,14175,1,4,0)
 ;;=4^E11.36
 ;;^UTILITY(U,$J,358.3,14175,2)
 ;;=^5002642
 ;;^UTILITY(U,$J,358.3,14176,0)
 ;;=E11.359^^82^774^20
 ;;^UTILITY(U,$J,358.3,14176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14176,1,3,0)
 ;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,14176,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,14176,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,14177,0)
 ;;=E11.351^^82^774^21
 ;;^UTILITY(U,$J,358.3,14177,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14177,1,3,0)
 ;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,14177,1,4,0)
 ;;=4^E11.351
 ;;^UTILITY(U,$J,358.3,14177,2)
 ;;=^5002640
 ;;^UTILITY(U,$J,358.3,14178,0)
 ;;=E11.349^^82^774^22
 ;;^UTILITY(U,$J,358.3,14178,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14178,1,3,0)
 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,14178,1,4,0)
 ;;=4^E11.349
 ;;^UTILITY(U,$J,358.3,14178,2)
 ;;=^5002639
 ;;^UTILITY(U,$J,358.3,14179,0)
 ;;=E11.341^^82^774^23
 ;;^UTILITY(U,$J,358.3,14179,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14179,1,3,0)
 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,14179,1,4,0)
 ;;=4^E11.341
 ;;^UTILITY(U,$J,358.3,14179,2)
 ;;=^5002638
 ;;^UTILITY(U,$J,358.3,14180,0)
 ;;=E11.339^^82^774^18
